Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJia Wang

Discussion

Loading...

Member takes

Overview

Findings show improved complete response and reduced adverse events in relapsed/refractory B-cell lymphoma with glofitamab, indicating T cell exhaustion may enhance treatment outcomes.

Key Points

  • This research assesses the efficacy, safety, and T-cell dynamics of glofitamab in patients with relapsed/refractory B-cell lymphoma.
  • Patients received obinutuzumab before glofitamab monotherapy.
  • Glofitamab was administered at varying dosages over a maximum of 6 cycles.
  • Clinical responses, cytokine levels, and T cell populations were monitored throughout treatment.
  • Overall response rate increased from 6/8 to 7/8 after 4 treatment cycles.
  • Complete response improved from 0/8 to 3/8 after multiple cycles.
  • Cytokine release syndrome occurred in 6/8 patients, primarily Grade 1-2.

Cite This Study

Jia Wang (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3d8https://doi.org/10.1182/blood-2025-7266
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.2024 · 15 citations
  2. 2Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study2024 · 72 citations
  3. 3Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma2025
  4. 4Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations
  5. 5Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025